Post-Approval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States–Based Rheumatoid Arthritis Registry
ACR Open Rheumatol. 2021 Feb 11.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
ACR Open Rheumatol. 2021 Feb 11.
Arthritis Res Ther 2021;23(1):3.
J Eur Acad Dermatol Venereol 2020;34:2809–2820.
Int Immunopharmacol. 2020 Sep;86:106748.
Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.
Arth Res Ther 2020;22:115 doi.org/10.1186/s13075-020-02199-8
Ann Rheum Dis. 2020 10.1136/annrheumdis-2019-216566
Clin Transl Sci . 2020 Mar;13(2):325-336. doi: 10.1111/cts.12713. Epub 2019 Nov 29.
Clin Drug Investig .2020 Jan;40(1):65-72. doi: 10.1007/s40261-019-00863-9.
Rheumatology (Oxford) 2019;58(11):2051–60